Pular para o conteúdo
Complexo esclerose tuberosa
ORPHA:805CID-10 · Q85.1CID-11 · LD2D.2DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
Visão / ocularInício todas idadesHerança AD
Também conhecida comoSíndrome BournevilleTSC
Sinônimos clínicos: Síndrome Bourneville

É uma doença genética que se manifesta por convulsões, deficiência intelectual, atraso no desenvolvimento e lesões na pele e nos olhos. Os primeiros sinais geralmente surgem na fase de bebê ou criança, mas em casos raros podem não aparecer até os 20 ou 30 anos de idade.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A esclerose tuberosa complexa é um distúrbio genético caracterizado pelo crescimento de numerosos tumores não cancerosos (benignos) em muitas partes do corpo. Esses tumores podem ocorrer no cérebro, rins, coração, pele e outros órgãos, em alguns casos levando a problemas de saúde significativos. A esclerose tuberosa complexa também causa problemas de desenvolvimento, e os sinais e sintomas da condição variam de pessoa para pessoa.

A esclerose tuberosa complexa frequentemente afeta o cérebro, com alguns indivíduos afetados apresentando crescimentos benignos na superfície externa do cérebro (córtex cerebral) conhecidos como tubérculos corticais. Pessoas com a condição muitas vezes desenvolvem um padrão de comportamentos chamado transtornos neuropsiquiátricos associados à TSC (TAND). Esses transtornos incluem hiperatividade, agressão, condições psiquiátricas, deficiência intelectual e problemas de comunicação e interação social (transtorno do espectro autista). Além disso, pessoas com a condição podem ter transtorno de déficit de atenção/hiperatividade (ADHD) ou convulsões.

Tumores renais são comuns em pessoas com a condição; esses crescimentos podem causar problemas graves na função renal e podem ser potencialmente mortais em alguns casos. Além disso, tumores podem se desenvolver no coração (rhabdomioma cardíaco) e no tecido sensível à luz na parte posterior do olho (a retina). Algumas mulheres com a condição desenvolvem linfangioleiomiomatose (LAM), que é uma doença pulmonar caracterizada pelo crescimento anormal de tecido semelhante ao músculo liso nos pulmões, causando tosse, falta de ar, dor no peito e colapso pulmonar.

Praticamente todas as pessoas afetadas apresentam anomalias cutâneas, incluindo manchas de pele incomumente clara, áreas de pele elevada e espessada, e crescimentos sob as unhas. Tumores no rosto chamados angiofibromas faciais também são comuns a partir da infância. Às vezes, indivíduos afetados apresentam áreas de dano ósseo ou dental.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

É uma doença genética que se manifesta por convulsões, deficiência intelectual, atraso no desenvolvimento e lesões na pele e nos olhos. Os primeiros sinais geralmente surgem na fase de bebê ou criança, mas em casos raros podem não aparecer até os 20 ou 30 anos de idade.

Pesquisas ativas
31 ensaios
111 total registrados no ClinicalTrials.gov
Publicações científicas
5.376 artigos
Último publicado: 2026 Apr 5
Em pesquisa
3 moléculas
EVEROLIMUS, GANAXOLONE, SIROLIMUS

O que está sendo pesquisado

3 moléculas em estudo — nenhuma com registro para esta doença
Ver detalhes e fases →
EVEROLIMUSGANAXOLONESIROLIMUS
Aparecer aqui significa que a molécula foi estudada nesta doença, não que trate. Converse com seu médico.

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
1.58
Taiwan, Province of China
Início
All ages
🏥
SUS: Cobertura mínimaScore: 15%
5 procedimentos SIGTAPCID-10: Q85.1
🇧🇷Dados SUS / DATASUS
EXAMES E PROCEDIMENTOS RELACIONADOS (5)
•
Cariótipo — bandas G, Q ou R
•
Pesquisa de microdeleções/microduplicações por FISH
•
Sequenciamento completo do exoma (WES)
•
Dosagem de alfa-fetoproteína
•
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
17 sintomas
🫘
Rins
8 sintomas
📏
Crescimento
6 sintomas
🧬
Pele e cabelo
5 sintomas
👁️
Olhos
5 sintomas
🫁
Pulmão
4 sintomas

+ 29 sintomas em outras categorias

Características mais comuns

90%prev.
Mácula hipomelanótica
Muito frequente (99-80%)
90%prev.
Nódulos subependimários
Muito frequente (99-80%)
90%prev.
Anormalidade do rim
Muito frequente (99-80%)
90%prev.
Displasia cortical
Muito frequente (99-80%)
90%prev.
Comportamento atípico
Muito frequente (99-80%)
90%prev.
Anormalidade generalizada da pele
Muito frequente (99-80%)
83sintomas
Muito frequente (8)
Frequente (27)
Ocasional (14)
Muito raro (13)
Sem dados (21)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 83 características clínicas mais associadas, ordenadas por frequência.

Mácula hipomelanóticaHypomelanotic macule
Muito frequente (99-80%)90%
Nódulos subependimáriosSubependymal nodules
Muito frequente (99-80%)90%
Anormalidade do rimAbnormality of the kidney
Muito frequente (99-80%)90%
Displasia corticalCortical dysplasia
Muito frequente (99-80%)90%
Comportamento atípicoAtypical behavior
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico5.376PubMed
Últimos 10 anos200publicações
Pico2025107 papers
Linha do tempo
2026Hoje · 2026🧪 1995Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Autosomal dominant.

Curadoria gene-doença

fontes oficiais
TSC1 TSC2
TSC1 TSC2
PanelApp · Tuberous sclerosisGenomics England
TSC1 TSC2
IFNGInterferon gammaModifying germline mutation inTolerante
VIAS BIOLÓGICAS (6)
Interferon gamma signalingIFNG signaling activates MAPKsRegulation of IFNG signalingRUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)
MECANISMO DE DOENÇA

Aplastic anemia

A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. It is characterized by peripheral pancytopenia and marrow hypoplasia.

EXPRESSÃO TECIDUAL(Baixa expressão)
Sangue
1.1 TPM
Baço
0.9 TPM
Pulmão
0.9 TPM
Linfócitos
0.9 TPM
Adipose Visceral Omentum
0.3 TPM
OUTRAS DOENÇAS (8)
immunodeficiency 69tuberous sclerosisidiopathic aplastic anemiatuberous sclerosis 2
HGNC:5438UniProt:P01579
TSC2TuberinDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (6)
Energy dependent regulation of mTOR by LKB1-AMPKTP53 Regulates Metabolic GenesInhibition of TSC complex formation by PKBTBC/RABGAPsAKT phosphorylates targets in the cytosol
MECANISMO DE DOENÇA

Tuberous sclerosis 2

An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
133.2 TPM
Cérebro - Hemisfério cerebelar
103.9 TPM
Pituitária
94.3 TPM
Tireoide
88.0 TPM
Testículo
86.3 TPM
OUTRAS DOENÇAS (9)
lymphangioleiomyomatosistuberous sclerosis 2isolated focal cortical dysplasia type IItuberous sclerosis
HGNC:12363UniProt:P49815
TSC1HamartinDisease-causing germline mutation(s) inAltamente restrito
VIAS BIOLÓGICAS (5)
MacroautophagyEnergy dependent regulation of mTOR by LKB1-AMPKTP53 Regulates Metabolic GenesInhibition of TSC complex formation by PKBTBC/RABGAPs
MECANISMO DE DOENÇA

Tuberous sclerosis 1

An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
59.5 TPM
Cérebro - Hemisfério cerebelar
57.4 TPM
Nervo tibial
37.5 TPM
Ovário
36.5 TPM
Tireoide
35.7 TPM
OUTRAS DOENÇAS (7)
tuberous sclerosis 1isolated focal cortical dysplasia type IIlymphangioleiomyomatosistuberous sclerosis
HGNC:12362UniProt:Q92574

Medicamentos e terapias

EVEROLIMUSPhase 4

Mecanismo: FK506-binding protein 1A inhibitor

GANAXOLONEPhase 3

Mecanismo: GABA-A receptor; anion channel positive allosteric modulator

SIROLIMUSPhase 3

Mecanismo: FK506-binding protein 1A inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

3.962 variantes patogênicas registradas no ClinVar.

🧬 IFNG: GRCh37/hg19 12q15-21.1(chr12:68168330-72795051)x1 ()
🧬 IFNG: GRCh37/hg19 12q14.1-15(chr12:61755618-70035424)x1 ()
🧬 IFNG: GRCh37/hg19 12q14.2-15(chr12:64609458-70352103)x1 ()
🧬 IFNG: GRCh37/hg19 12q14.3-15(chr12:66045645-68872343)x1 ()
🧬 IFNG: GRCh37/hg19 12q14.3-21.1(chr12:65251705-75263379)x1 ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado6
3Fase 320
2Fase 228
1Fase 16
·Pré-clínico43
Medicamentos catalogadosEnsaios clínicos· 3 medicamentos · 100 ensaios
✓ Aprovados — podem ser usados hoje
EVEROLIMUS
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Complexo esclerose tuberosa

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 14 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

19 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07287202 · Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxali…Recrutando
PHASE1, PHASE2🇦🇺 Austrália
NCT07575347 · Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)Recrutando
Romania
NCT07561957 · A Smart Phone Application to Improve Adoption of the 2024 Ki…Recrutando
NA🇮🇪 Irlanda
NCT07369505 · Sapu003 in Advanced mTOR-sensitive Solid TumorsRecrutando
PHASE1🇦🇺 Austrália
NCT06081348 · Sertraline vs. Placebo in the Treatment of Anxiety in Childr…Recrutando
PHASE2🇨🇦 Canadá
NCT07403266 · Treatment With Full-spectrum Cannabis Extract of Refractory …Recrutando
PHASE3🇪🇸 Espanha
NCT06330350 · Qualitative Study in Patients With Genodermatoses and Health…Recrutando
🇳🇱 Países Baixos
NCT06160310 · Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Preg…Recrutando
🇺🇸 Estados Unidos
NCT05534672 · Placebo Controlled Study to Assess the Efficacy and Safety o…Recrutando
PHASE3🇵🇱 Polônia
NCT05104983 · Stopping TSC Onset and Progression 2B: Sirolimus TSC Epileps…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT06764602 · Observational, Retrospective, Multicenter, Nonprofit Study o…Recrutando
🇮🇹 Itália
NCT05676099 · TSC Biosample Repository and Natural History DatabaseRecrutando
🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT02890641 · Genetic and Electrophysiologic Study in Focal Drug-resistant…Recrutando
🇫🇷 França
NCT00001975 · Study of Skin Tumors in Tuberous SclerosisRecrutando
🇺🇸 Estados Unidos
NCT00001532 · Role of Genetic Factors in the Development of Lung DiseaseRecrutando
🇺🇸 Estados Unidos
NCT00001465 · Study of the Disease Process of LymphangioleiomyomatosisRecrutando
🇺🇸 Estados Unidos
NCT06879665 · TANDem-2: Closing the Gap to Interventions for TANDPor convite
NA🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT06330324 · Reproductive Options in Inherited Skin DiseasesPor convite
🇳🇱 Países Baixos
NCT03836300 · Parent and Infant Inter(X)Action Intervention (PIXI)Por convite
NA🇺🇸 Estados Unidos

Outros ensaios clínicos

111 ensaios clínicos encontrados, 31 ativos.

Distribuição por fase
NCT07843823 · Neurocutaneous Syndromes in Children: Prevalence and Clinica…Em breve
NCT07680322 · Safety and Efficacy of AV078 in Participants With Tuberous S…Em breve
PHASE2🇨🇦 Canadá
NCT05485831 · Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous S…Ativo
🇮🇹 Itália
NCT06392009 · Astroscape: A Study of Radiprodil on Safety, Tolerability, P…Ativo
PHASE1, PHASE2🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +5
NCT06139172 · Web Intervention for Parents of Youth With Genetic Syndromes…Ativo
NA🇺🇸 Estados Unidos
NCT05252585 · A Phase IV Study of Safety and Efficacy of Everolimus in Tai…Ativo
PHASE4🇹🇼 Taiwan
NCT05469373 · ESIS in Pediatric DREAtivo
🇺🇸 Estados Unidos
NCT05467397 · Feasibility of [11C]Acetate-PET in LAM and TSCAtivo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT05044819 · Assessment of Potential for Chronic Liver Injury in Particip…Ativo
PHASE4🇺🇸 Estados Unidos
NCT04198181 · The Effectiveness and Safety of Resective Epilepsy Surgery f…Ativo
🇨🇳 China
NCT02962414 · Roll-over Study to Collect and Assess Long-term Safety of Ev…Ativo
PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +15
NCT02461459 · Autism Spectrum Disorder (ASD) and Intellectual Disability (…Ativo
🇺🇸 Estados Unidos
NCT02325505 · Characterization of Patients With Tuberous Sclerosis Complex…Concluído
🇧🇷 Brasil
NCT06975605 · Phase 1, Open-label, Drug-drug Interaction Study to Assess E…Concluído
PHASE1🇦🇺 Austrália
NCT05864846 · A Study to Investigate Behavioral and Other Co-Occurring Out…Concluído
PHASE4🇨🇦 Canadá · 🇵🇱 Polônia · 🇬🇧 Reino Unido +1
NCT05626634 · Open-label, Long-term Safety Study of LP352 in Subjects With…Concluído
PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT06311474 · Remote Assessment and Intervention for Behavior Problems in …Concluído
NA🇺🇸 Estados Unidos
NCT05286632 · KidneYou - Innovative Digital TherapyConcluído
NA🇮🇹 Itália
NCT05495425 · Clinical Study of NPC-12Y Gel in Patients With Skin Lesions …Concluído
PHASE3🇯🇵 Japão
NCT05323370 · Lymphangioleiomyomatosis, a Study on Cathepsin KConcluído
🇫🇷 França
NCT05323734 · Adjunctive GNX Treatment Compared With Placebo in Children a…Concluído
PHASE3🇦🇺 Austrália · 🇨🇦 Canadá · 🇨🇳 China +7
NCT05059327 · Basimglurant (NOE-101) in Children, Adolescents, and Young A…Concluído
PHASE2🇮🇳 Índia · 🇮🇱 Israel · 🇮🇹 Itália +5
NCT05364021 · Study to Investigate LP352 in Subjects With Developmental an…Concluído
PHASE1, PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT05161494 · Gait in Rare DiseasesConcluído
🇧🇪 Bélgica
NCT05199402 · Clinical Trial Data Set Re-use With Statistical Methodologie…Concluído
🇫🇷 França
NCT04698538 · TSC Remote Assessment and InterventionConcluído
NA🇺🇸 Estados Unidos
NCT04595513 · Stopping TSC Onset and Progression 2: Epilepsy Prevention in…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT04285346 · Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by …Concluído
PHASE2🇺🇸 Estados Unidos
NCT04198207 · The Effectiveness and Safety of Vagus Nerve Stimulation for …Concluído
🇨🇳 China
NCT03826628 · Dose-Ranging Efficacy and Safety Study of Topical Rapamycin …Concluído
PHASE2, PHASE3🇦🇺 Austrália · 🇨🇿 Tchéquia · Hungary +6
NCT03525834 · Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adu…Concluído
PHASE4🇨🇳 China
NCT03650452 · A Phase 2, Multicenter, Randomized, Double-blind, Placebo-co…Concluído
PHASE2🇦🇺 Austrália · 🇨🇦 Canadá · 🇨🇳 China +5
NCT02849457 · Preventing Epilepsy Using Vigabatrin In Infants With Tuberou…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02544750 · An Open-label Extension Trial of Cannabidiol (GWP42003-P, CB…Concluído
PHASE3🇺🇸 Estados Unidos
NCT06789419 · Predicting Epileptogenic Tubers in Patients with Tuberous Sc…Concluído
NCT03276195 · Studies in Patients With Tuberous Sclerosis ComplexConcluído
🇺🇸 Estados Unidos
NCT02544763 · A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CB…Concluído
PHASE3🇦🇺 Austrália · 🇳🇱 Países Baixos · 🇵🇱 Polônia +3
NCT02634931 · Long-term Trial of Topical Sirolimus to Angiofibroma in Pati…Concluído
PHASE3🇯🇵 Japão
NCT02635789 · Phase III Trial of Topical Formulation of Sirolimus to Skin …Concluído
PHASE3🇯🇵 Japão
NCT02687633 · Early Behavioral Intervention to Improve Social Communicatio…Concluído
NA🇺🇸 Estados Unidos
NCT02201212 · Everolimus for Cancer With TSC1 or TSC2 MutationConcluído
PHASE2🇺🇸 Estados Unidos
NCT02061397 · Safety of Simvastatin in LAM and TSCConcluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT02451696 · A Pilot Study To Evaluate The Effects of Everolimus on Brain…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01906866 · Efficacy and Safety of Circadin® in the Treatment of Sleep D…Concluído
PHASE3🇫🇮 Finlândia · 🇫🇷 França · 🇳🇱 Países Baixos +2
NCT01853423 · Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamConcluído
PHASE1🇺🇸 Estados Unidos
NCT03140449 · Topical Rapamycin and Calcitriol for Angiofibroma of Tuberou…Concluído
PHASE3
NCT01929642 · Rapalogues for Autism Phenotype in TSC: A Feasibility StudyConcluído
PHASE2🇺🇸 Estados Unidos
NCT01713946 · A Placebo-controlled Study of Efficacy & Safety of 2 Trough-…Concluído
PHASE3🇦🇷 Argentina · 🇦🇺 Austrália · 🇧🇪 Bélgica +22
NCT01903681 · Assessment of the Pharmacokinetics of Circadin® in Children …Concluído
PHASE1🇳🇱 Países Baixos
NCT01780441 · Early Biomarkers of Autism in Infants With Tuberous Sclerosi…Concluído
🇺🇸 Estados Unidos
NCT01767779 · Potential EEG Biomarkers and Antiepileptogenic Strategies fo…Concluído
🇺🇸 Estados Unidos
NCT01526356 · Topical Rapamycin to Erase Angiofibromas in TSCConcluído
PHASE2🇦🇺 Austrália · 🇺🇸 Estados Unidos
NCT01289912 · Trial of RAD001 and Neurocognition in Tuberous Sclerosis Com…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01070316 · Everolimus (RAD001) Therapy for Epilepsy in Patients With Tu…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT01031901 · Topical Rapamycin Therapy to Alleviate Cutaneous Manifestati…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00789828 · Efficacy and Safety of Everolimus (RAD001) in Patients of Al…Concluído
PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +7
NCT00989742 · Doxycycline In Lymphangioleiomyomatosis (LAM)Concluído
PHASE4🇬🇧 Reino Unido
NCT00790400 · Efficacy and Safety of RAD001 in Patients Aged 18 and Over W…Concluído
PHASE3🇨🇦 Canadá · 🇫🇷 França · 🇩🇪 Alemanha +8
NCT00792766 · Long Term Follow Up for RAD001 Therapy of Angiomyolipomata i…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00598455 · Tuberous Sclerosis Complex Natural History Study: Renal Mani…Concluído
🇺🇸 Estados Unidos
NCT00552955 · Effect of Fasting on the Size of Abdominal Lymphatic Tumors …Concluído
🇺🇸 Estados Unidos
NCT00411619 · Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Pat…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00126672 · RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMASConcluído
PHASE2🇺🇸 Estados Unidos
NCT00457964 · RAD001 Therapy of Angiomyolipomata in Patients With TS Compl…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT00457808 · Rapamycin Therapy for Patients With Tuberous Sclerosis Compl…Concluído
PHASE2🇺🇸 Estados Unidos
NCT07327164 · Precision Medicine for Neurocutaneous Syndromes in Western C…Concluído
🇨🇳 China
NCT00001869 · Official Record of Patients Diagnosed With Lymphangioleiomyo…Concluído
🇺🇸 Estados Unidos
NCT05867576 · Acceptance and Commitment Therapy in Tuberous Sclerosis Comp…UNKNOWN
NA🇬🇧 Reino Unido
NCT04987463 · Efficacy and Safety of Rapamycin Versus Vigabatrin in the Pr…UNKNOWN
PHASE2, PHASE3🇵🇱 Polônia
NCT04112537 · Dermatologic Patterns of Tuberous Sclerosis Patients and Som…UNKNOWN
🇫🇷 França
NCT03356769 · Aspirin as an add-on Treatment of Refractory Epilepsy in Tub…UNKNOWN
PHASE2🇨🇳 China
NCT03422367 · JASPER Early Intervention for Tuberous SclerosisUNKNOWN
NA🇺🇸 Estados Unidos
NCT03326765 · Characterizing Sleep Disorders in Children and Adults With T…UNKNOWN
NA🇧🇪 Bélgica
NCT02887781 · Clinical Presentation and Renal Outcome of Patients With Tub…UNKNOWN
🇫🇷 França
NCT02436746 · The Cognitive Variability in NF1 and TSC Monozygotic TwinsUNKNOWN
🇳🇱 Países Baixos
NCT02098759 · Long-term, Prospective Study Evaluating Clinical and Molecul…UNKNOWN
NA🇦🇹 Áustria · 🇧🇪 Bélgica · 🇨🇿 Tchéquia +5
NCT01730209 · Efficacy of RAD001/Everolimus in Autism and NeuroPsychologic…UNKNOWN
PHASE2, PHASE3🇳🇱 Países Baixos
NCT01954693 · A Study of Everolimus in the Treatment of Neurocognitive Pro…UNKNOWN
PHASE2🇬🇧 Reino Unido
NCT00490789 · Trial of Efficacy and Safety of Sirolimus in Tuberous Sclero…UNKNOWN
PHASE2🇬🇧 Reino Unido
NCT06965881 · Study to Evaluate the Pharmacokinetics and Safety Effects Fo…Encerrado
PHASE1🇦🇺 Austrália
NCT05604170 · Open-label Study of Adjunctive GNX Treatment in Children and…Encerrado
PHASE3🇦🇺 Austrália · 🇨🇦 Canadá · 🇨🇳 China +7
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Ensaio randomizado
Timeline de publicações
3.379 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 3.379

#1

Contributors to Parenting Stress in Tuberous Sclerosis Complex at Preschool Age.

Pediatric neurology2026 Feb 25

This study aimed to identify child and family characteristics contributing to parenting stress in parents of young children with tuberous sclerosis complex (TSC). Data on 98 children with TSC aged 3 to 6 years old were gathered as part of a study on the assessment and treatment of behavior problems in TSC. Families recruited throughout North America participated in telehealth assessments, in which child developmental, behavioral, and medical history data were gathered, along with family demographics and parenting stress. The relationship between parenting stress and child and family variables was investigated through univariate and multivariate analysis. A substantial minority of parents reported elevated levels of parenting stress, with the greatest elevations in perceptions of their child as difficult. Higher child externalizing problems, internalizing problems, and social withdrawal contributed to greater parenting stress in multivariate analysis. Lower child adaptive skills were associated with more parenting stress. Financial problems related to medical care and child seizure severity also contributed to variation in parenting stress. Results offer novel insights into specific behavioral, developmental, and medical domains that present challenges when parenting a young child with TSC. Challenging child behaviors are a primary driver of parenting stress in families of preschool-aged children with TSC, along with other common traits, including social withdrawal and developmental delay. Addressing contributors to parenting stress through behavioral interventions and psychoeducation about expected developmental trajectories may enable parents to better manage the many demands of caring for a young child with TSC.

#2

Tuberous sclerosis complex.

Nature reviews. Disease primers2026 Mar 12

Tuberous sclerosis complex (TSC) is a rare genetic disease caused by heterozygous loss-of-function variants in TSC1 or TSC2. Patients present with benign tumours known as hamartomas in the brain, eyes, lungs, kidneys, heart and skin. Many hamartomas contain mosaic second hit variants in TSC1 or TSC2. The most disabling features of TSC include epilepsy and TSC-associated neuropsychiatric disorders (TAND) such as intellectual disability and autism spectrum disorder. Remarkable progress has been made both in understanding the pathogenesis of TSC and in its clinical management, largely due to the discovery of the link between TSC1 and TSC2 and the mechanistic target of rapamycin (mTOR) signalling pathway. TSC1 and TSC2 form a protein complex that inhibits mTOR. Naturally occurring inhibitors of mTOR (rapamycin) and its analogues, collectively known as rapalogues, have been used to test various hypotheses in preclinical models and are approved for the treatment of several manifestations of TSC. Approved drug treatments (rapalogues) exist for subependymal giant cell astrocytomas, renal angiomyolipomas, pulmonary lymphangioleiomyomatosis, facial angiofibromas and refractory seizures. However, there is still an unmet need for effective treatment of TAND and refractory epilepsy, despite the available medical and surgical options.

#3

An Open-Source Pipeline for Calcium Imaging and All-Optical Physiology in Human Stem Cell-Derived Neurons.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)2026 Mar 09

High-throughput, single-cell resolution profiling of neuronal activity is critical for understanding brain function and modeling neurological disorders, yet existing approaches are often limited by scalability and manual workflows. Here, we present an open-source, scalable imaging and analysis platform that integrates optogenetic stimulation, calcium imaging, automated acquisition, single-cell and network analyses. The platform enables robust quantification of spontaneous and evoked neuronal activity across hundreds of human stem cell-derived neurons over multiple timepoints, supporting functional phenotyping at both cellular and network levels. We demonstrate the versatility of the platform across multiple disease-relevant contexts, including models of CDKL5 Deficiency, SSADH Deficiency, and tuberous sclerosis complex (TSC). Additionally, we generate CRISPR-Cas9 knock-in hiPSC lines expressing GCaMP6s and demonstrate partial reversal through pharmacological intervention in TSC. By linking single-cell dynamics to network-level measures, this platform provides a generalizable framework for scalable functional phenotyping and high-throughput screening in human neuronal models.

#4

Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes.

Pediatric neurology2026 Feb 09

Language impairments impact 72% of individuals with tuberous sclerosis complex (TSC). Nevertheless, evaluations are often delayed until children are 7 years old or older. Earlier prediction of language impairment is needed. Infant vocal behavior is a predictor of language development in typically developing children, but early vocal development had not been studied in TSC until recent research on 38 infants. In this study, the canonical babbling ratio (CBR) and volubility, key indicators of infant vocal behavior, were low. CBR reflects the proportion of syllables that are canonical and volubility reflects either production of utterances or syllables per minute. The present study has the following three goals: (1) To expand CBR and volubility characterization, (2) To evaluate predictiveness of CBR and volubility for autism spectrum disorder (ASD) and language outcomes, and (3) To determine if the contribution of CBR to prediction is independent of other known predictors. We analyzed 202 recordings at 12 months for infants with TSC. Linear regression predicted language outcomes from vocal measures. Then, stepwise multiple regression compared the relative predictiveness for language outcomes of CBR and other measures known to predict language outcomes. Finally, logistic regression tested for ASD prediction. CBR and volubility were lower in TSC than in prior typically developing data. CBR was predictive of language outcomes at 24 months for infants with TSC even when competing against other known predictors, but neither CBR nor volubility predicted ASD. CBR may have utility for early identification of language impairments in TSC.

#5

Development and validation of interpretable multimodal clinical-radiomics models for predicting epileptogenic foci and surgical outcomes in tuberous sclerosis complex: A multicenter study.

PLOS digital health2026 Feb

Precise localization and resection of epileptogenic (epi) foci from multiple cortical foci determine surgical outcomes in the tuberous sclerosis complex (TSC). Although the use of intracranial electroencephalography (EEG) for detecting epileptic discharges remains the gold standard for identifying epi foci, its invasiveness and cost limit clinical application. We aimed to develop and validate a noninvasive, clinically applicable predictive model for epi foci identification and surgical outcome assessment in patients with TSC. This multicenter study focused on three retrospective cohorts and one prospective cohort from three comprehensive epilepsy centers from June 2013 to October 2024. Comprehensive clinical and imaging data (CT, MRI, and 18F-FDG PET) of cortical foci were collected. Nineteen individual machine learning (ML) models and three ensemble ML models (voting, averaging and super-learner [SL]) were developed on the basis of the clinical and radiomics features of cortical foci. Model performance was evaluated by using the area under the curve (AUC), accuracy, precision, specificity, and sensitivity values, along with the F1 score, with additional validation being conducted via decision curve analysis (DCA) and calibration curves. Follow-up data were collected at 1, 3, and >5 years to validate the ability of the ML models to predict long-term postoperative outcomes. Non-epi foci were clustered by using the k-means algorithm to investigate the mechanisms underlying postoperative epileptogenic transformation. A web-based tool was developed to provide a user-friendly interface for clinical application. A total of 665 cortical foci (epi foci, n = 161; non-epi foci, n = 504) were included in this study. The model integrating multimodal clinical-radiomics features performed better than the individual models based only on single-modal clinical or radiomics features did. The ensemble SL model using clinical-radiomics features demonstrated the best stability and superior predictive performance compared to those of individual models and an additional two ensemble models in prospective (AUC: 0.92) and two retrospective cohorts (AUCs: 0.91 and 0.87); moreover, it outperformed previously reported prediction models. In addition, the SL model effectively predicted 1-, 3- and >5-year surgical outcomes (AUCs: 0.93, 0.91, and 0.92, respectively). K-means revealed two clusters of non-epi foci, including those foci with epileptogenic potential and those without, which were potentially confirmed by the follow-up data. The web-based tool significantly increased the accuracy of junior clinicians (from 0.61 to 0.78), which matched the accuracy of senior clinicians (0.80). The multimodal clinical-radiomics model represents a noninvasive tool for predicting epi foci, guiding preoperative evaluation, addressing diagnostic discrepancies and enabling personalized treatment strategies in patients with TSC. The clinical application of artificial intelligence (AI)-driven clinical-radiomics models provides a useful tool and auxiliary reference for clinicians in preoperative epileptogenic foci prediction.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC2.677 artigos no totalmostrando 197

2026

Neuronal expression of Retinoid-Related Orphan Receptor Gamma (RORγ) and revisiting its role in the Central Nervous System.

bioRxiv : the preprint server for biology
2026

Safety Signals Enable Single-Episode Active Avoidance paradigm and Expose Threat Generalization in Tuberous Sclerosis Complex.

bioRxiv : the preprint server for biology
2026

Contributors to Parenting Stress in Tuberous Sclerosis Complex at Preschool Age.

Pediatric neurology
2026

Tuberous sclerosis complex.

Nature reviews. Disease primers
2026

Late diagnosis and effective everolimus treatment in a familial case of tuberous sclerosis complex: a case report.

Frontiers in genetics
2026

Extracellular Polysaccharides of Eurotium cristatum from Fu Brick Tea Ameliorated Type 2 Diabetes in Mice by Remodeling of Gut Microbiota-Dependent Tryptophan Metabolism to Activate the Hepatic AhR/TSC2/mTORC1 Axis.

Journal of agricultural and food chemistry
2026

High-frequency ultrasound in genodermatoses.

Journal of ultrasound
2026

An Open-Source Pipeline for Calcium Imaging and All-Optical Physiology in Human Stem Cell-Derived Neurons.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Early Vocal Development in Tuberous Sclerosis Complex Predicts Language but Not Autism Outcomes.

Pediatric neurology
2026

Interpretable EEG biomarkers for neurological disease models in mice using bag-of-waves classifiers.

Journal of neural engineering
2026

Merritt-Putnam Symposium | Tumor-Associated Epilepsy and Epilepsy-Associated Tumors: Exploring the Bidirectional Crosstalk Between Tumors and Seizures.

Epilepsy currents
2026

Multicystic Kidney Disease in a Family With Tuberous Sclerosis Complex.

Nephrology (Carlton, Vic.)
2026

Landscaping evidence on first-line therapies for infantile epileptic spasms syndrome: An umbrella review.

Epilepsy research
2026

White matter abnormalities in tuberous sclerosis complex: a systematic review of diffusion tensor imaging studies.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Development and validation of interpretable multimodal clinical-radiomics models for predicting epileptogenic foci and surgical outcomes in tuberous sclerosis complex: A multicenter study.

PLOS digital health
2025

Clinical characteristics and outcomes of pediatric cardiac masses: A 20-year retrospective single-center experience.

Annals of pediatric cardiology
2026

Multifocal micronodular pneumocyte hyperplasia in the absence of tuberous sclerosis complex: A case report.

Radiology case reports
2026

Nitric Oxide-Mediated S-Nitrosylation of TSC2 Drives mTOR dysregulation across Shank3 and Cntnap2 Models of Autism Spectrum Disorder.

Molecular psychiatry
2026

Dual regulatory roles of CPT1C in chronic stress-induced depression-related outcomes.

Molecular psychiatry
2026

Educational attainment of individuals with lymphangioleiomyomatosis is a determinant of timely diagnosis and treatment uptake.

Orphanet journal of rare diseases
2026

Case Report: A case of ruptured renal epithelioid angiomyolipoma leading to the diagnosis of TSC2/PKD1 contiguous gene syndrome.

Frontiers in pediatrics
2026

TSC2/PKD1 contiguous gene deletion syndrome.

Kidney international
2026

Severe Renal Phenotype Across A Multigenerational Tuberous Sclerosis Complex (TSC) Family.

Molecular genetics &amp; genomic medicine
2026

Long-term outcome in children with infantile epileptic spasms syndrome: a multicenter retrospective study in Korea.

Clinical and experimental pediatrics
2026

Clinically Silent Seizures in Neonates with Tuberous Sclerosis: An International Case Series.

Neonatology
2026

TSC2 GAP Domain V1646Cfs*7 Variant Alters Protein Stability and Interaction Networks in Tuberous Sclerosis Complex.

Neurology. Genetics
2026

Retinal Astrocytic Hamartoma in a Child With Neurofibromatosis Type 1 Treated With Selumetinib.

Pediatrics
2026

Integration of intraoperative ultrasound and depth-electrode electrocorticography for resection guidance in epilepsy surgery: technical workflow and feasibility.

Acta neurochirurgica
2026

Case Report: mTOR inhibitor treatment for epithelioid angiomyolipoma harboring biallelic TSC2 mutations.

Frontiers in oncology
2025

Clinical profiles of tuberous sclerosis complex: A regionally based survey.

Brain &amp; development
2026

TSC-associated microglial hyperactivity: enhanced calcium signaling, metabolism, and phagocytosis.

Acta neuropathologica
2026

Genkwanin enhances survival of rat random skin flap: promoting autophagic flux by modulation of AMPK/TSC2/mTOR signaling pathway through SIRT1.

Biochemical pharmacology
2026

Bidirectional sleep-seizure interactions and orexin in a mouse model of tuberous sclerosis complex-related epilepsy.

Epilepsia
2026

Impact of prenatal sirolimus on cardiac rhabdomyomas and brain tubers.

Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
2026

Parameter-efficient convolutional neural network for drug treatment outcome studies of pediatric epilepsy.

Scientific reports
2026

Seizure and aspiration complicating acute expanding epidural hematoma in a tuberous sclerosis adolescent: a case report of clinical and surgical emergency.

BMC neurology
2026

Molecular convergence enables precision medicine for pediatric low grade gliomas.

Discover oncology
2026

Tuberous sclerosis complex with multisystem involvement: A case report.

The Journal of international medical research
2026

mTOR pathway mediates the endoplasmic reticulum stress -apoptosis of CD4+ T cell through inhibiting autophagy flux in sepsis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]
2026

Rhabdomyomas of the Mitral Valve: Case Series and Conservative Management Approach.

Pediatric cardiology
2026

Jumping-induced hypomotor seizure in a toddler with tuberous sclerosis complex.

Epileptic disorders : international epilepsy journal with videotape
2026

Long-Term Impact of Cenobamate on Cognition, Adaptive Behavior, and Quality of Life in Patients with Tuberous Sclerosis Complex.

Neurology and therapy
2026

Successful Everolimus Therapy for Atrioventricular Block Due to Cardiac Rhabdomyoma Associated With Tuberous Sclerosis Complex.

JACC. Case reports
2026

Development and validation of the Klinefelter-Associated Neurodevelopmental Difficulties (KAND) Checklist: a three-phase mixed-methods study.

Journal of neurodevelopmental disorders
2025

Quality of life and disease burden in tuberous sclerosis and comparison with the population with idiopathic autism spectrum disorder: an investigation conducted through questionnaires and clinical data collection in the pediatric population.

Frontiers in psychiatry
2026

Investigation of risk factors for autism spectrum disorder in children with tuberous sclerosis complex.

BMC psychiatry
2026

Dual renal pathologies in tuberous sclerosis complex: bilateral renal angiomyolipomas and concurrent left renal cell carcinoma.

BMJ case reports
2026

Malignant Progression of Subependymal Giant Cell Astrocytoma-Imitating Fibrous Meningioma in a Child Carrying a Germline <italic>CHEK2</italic> Mutation.

Pathobiology : journal of immunopathology, molecular and cellular biology
2026

A rare early-onset bilateral renal cysts, focal seizures in a 1-year-old male with tuberous sclerosis and No mutation identified.

Oxford medical case reports
2026

Possible earliest depiction of tuberous sclerosis complex in Bernardo de' Rossi (1468-1527).

Journal of neurology
2026

G Protein-Coupled Receptor 32 Contributes to Inflammation Resolution and Neuronal Excitability Dysfunction in Patients With Focal Cortical Dysplasia IIb and Tuberous Sclerosis Complex.

Neuropathology and applied neurobiology
2026

Alternative Lengthening of Telomeres in Malignant Perivascular Epithelioid Cell Neoplasms: Correlation With Molecular Features Including ATRX Gene Mutation Status.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
2026

Seizure outcomes after VNS therapy in children with drug-resistant epilepsy due to monogenic etiologies versus malformations of cortical development.

Journal of neurosurgery. Pediatrics
2025

Epilepsy, neuroinflammation and cannabidiol What do we know thus far?

Frontiers in pharmacology
2026

A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events.

Epilepsy research
2026

High prevalence of orocutaneous features in Yemeni patients with tuberous sclerosis complex.

JAAD international
2025

Intraoral Giant Cell Fibroma in a Young Patient with Tuberous Sclerosis Complex: A Case Report of a Rare Occurrence.

International journal of clinical pediatric dentistry
2026

Non-syndromic Multifocal Low-Grade Oncocytic Renal Tumors, Including Microtumors, in End-Stage Renal Disease Kidneys with Synchronous Non-TSC Renal Cell Neoplasms.

International journal of surgical pathology
2025

Autism Observation Scale for Infants: Systematic Review and Meta-Analysis in Samples at Increased Likelihood of Autism Spectrum Disorders.

Review journal of autism and developmental disorders
2026

Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma.

European urology open science
2026

Rasd2 Knockout Exaggerates the Hearing Loss Phenotype of Tsc1-Deficient Mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

MRI features of joint capsule-originating hamartomas in a pediatric patient with tuberous sclerosis: a novel case report.

Skeletal radiology
2026

Delayed Diagnosis of Tuberous Sclerosis Complex: A Case Report of Abdominal Distension, Pain, and Severe Anemia.

Clinical case reports
2026

Prenatal ultrasound diagnosis of fetal cardiac rhabdomyoma and analysis of clinical outcomes.

Quantitative imaging in medicine and surgery
2026

Oroxylin A Suppresses Pathological Vascular Smooth Muscle Cell Phenotypic Switching and Neointima Formation Through Hindering TSC2/mTORC1/HIF-1-Dependent Glycolysis.

Phytotherapy research : PTR
2026

Ictal vomiting as the first manifestation of Tuberous Sclerosis Complex: report of two pediatric cases.

Italian journal of pediatrics
2026

Recent advances in understanding the pathogenesis, diagnosis, and treatment of tuberous sclerosis complex (TSC)-associated Lymphangioleiomyomatosis.

Biochemical pharmacology
2026

Chromophobe thyroid carcinoma: a distinct entity associated with TSC gene alterations.

Virchows Archiv : an international journal of pathology
2026

Cutaneous manifestations of tuberous sclerosis complex in adults.

Journal of the American Academy of Dermatology
2026

Collagen Deposition in Tuberous Sclerosis Complex Is Driven Through KDM6A-Mediated Activation of ERK/SNAI1 Signaling.

Clinical genetics
2026

Fibroma-Like PEComa as an Early Indicator of Tuberous Sclerosis Complex: Confirmed With Strong GPNMB Expression and TSC2 Germline Mutation.

International journal of surgical pathology
2026

Smart bio-implants for seizure prediction in tuberous sclerosis complex.

Annals of medicine and surgery (2012)
2026

Low-Level Mosaicism in Tuberous Sclerosis Complex (TSC): Diagnostic and Clinical Implications From Two Novel Cases and Literature Review.

American journal of medical genetics. Part A
2026

Anti-seizure potential of J4, an equilibrative nucleoside transporter 1 inhibitor, in a mouse model of tuberous sclerosis complex in response to pentylenetetrazol.

Cell &amp; bioscience
2026

TSC2 is a positive master regulator of cellulase production by affecting protein secretion in Trichoderma reesei.

International journal of biological macromolecules
2025

Deployable seizure forecasting requires clinically meaningful performance: Response to Stirling et al.

Epilepsia
2025

Infantile Spasms (West Syndrome): Integrating Genetic, Neurotrophic, and Hormonal Mechanisms Toward Precision Therapy.

Medicina (Kaunas, Lithuania)
2025

Shagreen Patch in Tuberous Sclerosis Complex at High-Frequency Ultrasound.

Diagnostics (Basel, Switzerland)
2025

Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications.

Biomolecules
2025

A Systematic Review of Cutaneous Hypopigmentation Disorder Associated with Neurologic Involvement.

Children (Basel, Switzerland)
2026

The correlation between tuber burden and epilepsy onset in children with tuberous sclerosis complex.

Seizure
2025

TSC1 deficiency drives immune evasion in colorectal cancer via mTORC1-mediated dysregulation of PD-L1 sialylation.

Frontiers in immunology
2025

Fetal cardiac rhabdomyomas susceptible to prenatal treatment with mTOR inhibitors: literature review and proposal of a prenatal management algorithm.

Frontiers in medicine
2026

The critical role of the proto-oncogene c-Kit in TSC renal cystogenesis.

EMBO molecular medicine
2026

c-KIT joins the TSC ToolKIT: a new driver of renal cystogenesis.

EMBO molecular medicine
2026

Sensitivity Analysis of the Efficacy of Everolimus for Neurocognitive Symptoms in PTEN Hamartoma Tumor Syndrome.

Advances in therapy
2025

The Fourth Ventricle, A Rare Location for Subependymal Giant Cell Astrocytoma (SEGA): A Rare Case Report.

Clinical case reports
2025

High-salt diet induces immune-independent re-differentiation, metabolic shut down and cell cycle arrest of melanoma.

Cell death &amp; disease
2026

Daily Care Concerns Among Mothers of Children With Developmental and Epileptic Encephalopathies: A Qualitative Study Using In-Depth Interviews.

Child: care, health and development
2025

Neuroimaging in tuberous sclerosis complex: 7T MRI discloses a much larger number of tubers than conventional MRI.

AJNR. American journal of neuroradiology
2025

Conjunctival lymphangioma as the initial manifestation of tuberous sclerosis complex in a child.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2025

Predicting Epileptogenic Tubers in Patients With Tuberous Sclerosis Complex Using a Fusion Model Integrating Lesion Network Mapping and Machine Learning.

Annals of clinical and translational neurology
2025

Neuronal hyperactivity becomes mTORC1 independent due to transcriptional changes in tuberous sclerosis complex disease models.

Cell reports
2025

Genetic Association and Functional Prediction of PTEN and TSC1 3'UTR Variants in Autism Spectrum Disorder Among Tunisian Patients.

Molecular neurobiology
2025

Canagliflozin as a Potential Preclinical Therapy for Tuberous Sclerosis Complex: Inhibition of Tsc2 -/- Cell Proliferation via Cell Cycle Arrest and Mitochondrial Dysfunction.

Drug design, development and therapy
2026

Clinical outcomes following stereotactic MRI-guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy.

Epilepsia
2025

Cardiac rhabdomyomas in tuberous sclerosis complex: clinical manifestations and genotype correlations.

BMC pediatrics
2025

The Enigma of West Syndrome: A Case of Infantile Spasms Without Genetic Clues.

Case reports in pediatrics
2025

[Clinicopathological and molecular genetic characteristics of multifocal micronodular pneumocyte hyperplasia (MMPH)].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2026

Altered somatostatin receptor 3 expression and functional dysregulation in tuberous sclerosis complex.

Progress in neurobiology
2025

Gut microbiota signatures in tuberous sclerosis complex and epilepsy: a pilot study.

Frontiers in neuroscience
2026

TSC tunes progenitor balance and upper-layer neuron generation in neocortex.

Nature
2026

Renal epithelioid angiomyolipoma: A multi-institutional, international cohort study with emphasis on clinicopathologic prognostic indicators.

Urologic oncology
2025

Stereotactic radiosurgery for subependymal giant cell astrocytoma: Multi-institutional retrospective analysis of clinical and radiological outcomes.

Neurosurgical review
2025

Surgical trapping and everolimus therapy for a giant internal carotid aneurysm in pediatric tuberous sclerosis complex: case report and literature review.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Spatial gene expression profiling reveals the distinct microenvironment of tuberous sclerosis complex-associated angiomyolipoma.

Scientific reports
2025

Phenotypic individual clusters and metabolic tuber subtypes refine surgical strategy in tuberous sclerosis complex.

Brain : a journal of neurology
2025

Burden of illness in tuberous sclerosis complex-associated epilepsy: a systematic literature review of epidemiology, health-related quality of life, costs and resource use.

Orphanet journal of rare diseases
2025

Whole exome sequencing in fetal cardiac rhabdomyoma detected by ultrasonography: an analysis of 12 cases.

BMC pregnancy and childbirth
2025

Hereditary syndromes and RCC: what radiologists need to know.

Abdominal radiology (New York)
2025

Diagnosis and Management of Children With Tuberous Sclerosis Complex.

Journal of paediatrics and child health
2025

Multifocal micronodular pneumocyte hyperplasia in a patient with undiagnosed tuberous sclerosis: next-generation sequencing of a lung biopsy reveals TSC1 mutation-a case report.

Journal of medical case reports
2025

Prefrontal oxytocin receptor positive cells mediate stress-induced anxiety in tuberous sclerosis complex.

Communications biology
2026

Convolutional neural networks for automatic tuber segmentation and quantification of tuber burden in tuberous sclerosis complex.

Epilepsia
2025

Macrophages lacking TSC2 have mTORC1-dependent increased GPNMB and ameliorate ventricular dysfunction/remodeling after ischemia-reperfusion.

Scientific reports
2025

Focal postnatal deletion of Tsc2 causes epilepsy.

Frontiers in molecular neuroscience
2025

The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases.

Progress in neurobiology
2025

Resolution of brady- and tachyarrhythmias with everolimus in a child with tuberous sclerosis complex: A case report.

Pediatrics international : official journal of the Japan Pediatric Society
2025

Evolution in the use of epilepsy surgery in tuberous sclerosis complex. Analysis of the Pediatric Health Information System over two decades.

Seizure
2025

Uncomplexed-TSC1 deploys novel mTORC1-independent pathway to exacerbate the liver glycogen storage in TSC.

Cell death &amp; disease
2025

Xanthomatous giant cell renal cell carcinoma: clinicopathologic and molecular characterization of 2 additional cases with biallelic TSC2 mutations.

American journal of clinical pathology
2026

Unraveling the microRNA mosaic: mechanisms and implications in focal cortical neurodevelopmental disorders.

International journal of surgery (London, England)
2025

Kidneys in Children with Tuberous Sclerosis Complex-An Up-to-Date Review.

Journal of clinical medicine
2025

Cortical Tubers' Transformation in Pediatric Patients Diagnosed with Tuberous Sclerosis Complex: A Retrospective Longitudinal MRI Analysis.

Journal of clinical medicine
2025

Systematic review of indirect costs to families of children with developmental epileptic encephalopathies.

Orphanet journal of rare diseases
2025

Renal Epithelioid Angiomyolipoma: A Case Report.

Clinical case reports
2025

Novel Frameshift Deletion Pathogenic Variant Characterization in Tuberous Sclerosis-2 Using Exome Sequencing and Molecular Dynamics Simulation.

Biochemical genetics
2026

Tuberous sclerosis complex-associated renal cell carcinoma, an underappreciated form of familial renal cancer, is characterized by activation of the TFEB/TFE3 pathway.

Human molecular genetics
2025

[Application of nephron-sparing surgery in tuberous sclerosis complex associated renal angiomyolipoma].

Zhonghua wai ke za zhi [Chinese journal of surgery]
2025

Tuberous Sclerosis Complex Associated with Hypothyroidism: A Case Report.

Neurology India
2025

A Case of TSC2/PKD1 Contiguous Gene Deletion Syndrome With Proven Kidney Pathology.

Kidney medicine
2026

Limited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex.

Pediatric neurology
2025

Laparoscopic nephrectomy for giant ruptured renal angiomyolipoma in tuberous sclerosis: case report and literature review.

Frontiers in surgery
2025

Fetal therapy with mTOR inhibitors in cardiac rhabdomyoma and lymphatic malformations.

Best practice &amp; research. Clinical obstetrics &amp; gynaecology
2025

Dynamic Clamp Methods to Investigate Impaired Neuronal Excitability Associated with Autism.

Journal of visualized experiments : JoVE
2025

Renal Epithelioid Angiomyolipomas: Clinicopathological Features, Diagnosis, and Management.

Cancer diagnosis &amp; prognosis
2026

Loss of Tsc1 in Osterix-expressing cells leads to greater bone mass and strength in mice.

Bone
2025

Real-world efficacy and safety of cannabidiol in developmental and epileptic encephalopathies.

Epilepsia open
2025

Genetic Etiology of Developmental and Epileptic Encephalopathy in a Turkish Cohort: A Single-Center Study with Targeted Gene Panel and Whole Exome Sequencing.

Genes
2025

Retinal astrocytic hamartoma with/without tuberous sclerosis: A comparative analysis by multimodal imaging.

Indian journal of ophthalmology
2025

Case Report: Fetal cardiac rhabdomyoma caused by TSC1 mutation.

Frontiers in pediatrics
2026

A Retrospective Cross-Sectional Study of 142 Patients in a Multidisciplinary Tuberous Sclerosis Clinic.

Clinical genetics
2025

Relationship between cortical tuber subtypes and interictal epileptiform discharges in tuberous sclerosis complex: MRI and scalp-EEG study.

Seizure
2025

Efficacy and safety of vigabatrin as preventive therapy for children with tuberous sclerosis complex: A systematic review and meta-analysis.

Seizure
2025

Spontaneous Retroperitoneal Haemorrhage From Bilateral Renal Angiomyolipomas: A Case Report on a First Presentation of Tuberous Sclerosis Complex.

Cureus
2026

p53 Drives Lung Cancer Regression through a TSC2/TFEB-dependent Senescence Program.

Cancer discovery
2025

Cardiac Rhabdomyoma in a Neonate.

Journal of cardiovascular echography
2025

Current Perspectives on The Diagnosis and Management of Lymphangioleiomyomatosis.

Clinics in chest medicine
2025

"Tuberous sclerosis in Greece: A national cohort study on clinical features and rare manifestations".

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

Developmental and epileptic encephalopathies: From current care to future perspectives - insights from epilepsy centres in Lombardy, Italy.

Epilepsy &amp; behavior : E&amp;B
2025

Drug-Resistant Epilepsy in Individuals With Tuberous Sclerosis Complex: Don't Wait Too Long to Consider Surgery.

Neurology
2025

Resective Surgery for Drug-Resistant Epilepsy in Patients With Tuberous Sclerosis Complex: A Prospective Nationwide Multicenter Cohort Study.

Neurology
2025

Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selection.

Translational and clinical pharmacology
2026

NEAT1 Promotes Epileptogenesis in Tuberous Sclerosis Complex.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
2026

Rigorous evaluation of five models for e-diary-only seizure forecasting: Retrospective and prospective datasets do not outperform the Napkin method.

Epilepsia
2025

Aberrant HCN4 channel expression: Impacts on neuronal excitability and implications for epilepsy pathogenesis.

British journal of pharmacology
2025

mTOR dysregulation induces IL-6 and paracrine AT2 cell senescence impeding lung repair in lymphangioleiomyomatosis.

Nature communications
2025

Neurodevelopmental Outcomes From the PREVeNT Trial.

Pediatric neurology
2025

Trifluoperazine, an Antipsychotic Drug, Inhibits Viability of Cells Derived From SEGA and Cortical Tubers Cultured In Vitro.

Journal of neurochemistry
2026

Recent Advances in the Management of Seizures in Children.

Paediatric drugs
2025

Delayed TSC Diagnosis Presenting as End-Stage Renal Disease With Renal and Hepatic Angiomyolipoma: Case Report and Review.

Clinical case reports
2025

Renal Cell Carcinoma in a Girl With Tuberous Sclerosis Due to a New Mutation.

Journal of medical cases
2025

Successful resection of large subependymal giant cell astrocytoma using presurgical mammalian target of rapamycin inhibitor.

Surgical neurology international
2025

Common Causes of Hypopigmentation in Children.

Pediatrics in review
2025

Regulating osteogenic differentiation of bone marrow mesenchymal stem cells by mTORC1 signaling pathway inhibits bone defect repair in mice.

Journal of orthopaedic surgery and research
2025

Beyond the uterus: diagnostic puzzle unravelled as benign metastasising leiomyomatosis with retroperitoneal and pulmonary involvement.

BMJ case reports
2025

UCHL1 enhances TSC1 transcription by stabilizing FOXO1 through deubiquitination in knee osteoarthritis.

Histology and histopathology
2025

Primary Synovial Sarcoma of the Ethmoid Sinus in a Young Female: A Rare Case Associated With Tuberous Sclerosis Complex.

Ear, nose, &amp; throat journal
2026

Management of a Large Rhabdomyoma with Sirolimus and Antiarrhythmic Agents.

Pediatric cardiology
2025

Loss of tuberous sclerosis complex 2 confers inflammation via dysregulation of nuclear factor kappa-light-chain-enhancer of activated B cells.

Journal of inflammation (London, England)
2025

Late failure of Everolimus in a patient with tuberous sclerosis complex after 10 years of effective response: an illustrative case.

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
2025

Coexistence of Renal Cell Carcinoma and Psoriasis in Tuberous Sclerosis Complex: A Shared mTOR Pathway Pathogenesis?

Clinical case reports
2025

Single nuclei transcriptomics reveals cellular diversity in TSC subependymal giant cell astrocytomas.

iScience
2025

Cell-cell communication dysregulation in tuberous sclerosis complex cortical tubers and focal cortical dysplasia.

Acta neuropathologica communications
2025

Availability and affordability of cannabinoids for epilepsy treatment across different geographic settings-A survey from the ILAE Plant-Based Therapy Task Force.

Epilepsia
2026

Clinicopathological and molecular characterization of seven rare cases of renal cell carcinoma with hemangioblastoma-like features: Expanding the morphological spectrum of renal tumours with tuberous sclerosis complex/mammalian target of rapamycin mutations.

Histopathology
2025

Huge cardiac rhabdomyoma in a neonate: A surgical challenge.

Annals of pediatric cardiology
2025

Progress in genetic mechanisms and precise treatment of neurocutaneous syndrome-related epilepsy.

Frontiers in neurology
2025

Genetic epilepsies as a cause of seizures in Neonates.

Seminars in perinatology
2025

High-throughput bioprinting to produce micropatterned neuroepithelial tissues and model TSC2-deficient brain malformations.

Cell reports methods
2025

Structural basis for mTORC1 activation on the lysosomal membrane.

Nature
2026

Spectrum of epileptogenicity in different cortical tuber radiological subtypes: A stereoelectroencephalographic study.

Epilepsia
2025

Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma.

Cancer research
2025

AAV hamartin gene therapy in a stochastic, cerebral mouse model of tuberous sclerosis type 1.

Molecular therapy. Methods &amp; clinical development
2026

Extracellular Matrix and Fibroblast Activation in Lymphangioleiomyomatosis.

American journal of respiratory cell and molecular biology
2025

Death-associated protein kinase 1: a double-edged sword in health and disease.

Frontiers in immunology
2025

Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transduction.

Life science alliance
2025

Inflammatory, Functional, and Compositional Changes of the Uterine Immune Microenvironment in a Lymphangioleiomyomatosis Mouse Model.

Journal of cellular immunology
2025

[Low Abuse Potential of Plant-Derived Highly Purified Cannabidiol: A Narrative Review].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
2025

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells.

Cancers
2025

Unmet needs and challenges faced by caregivers in tuberous sclerosis complex: An integrative review.

Epilepsy &amp; behavior : E&amp;B
2025

Cutaneous manifestations-associated with tuberous sclerosis complex and the use of topical rapamycin in the United States: a sub-analysis of an international survey of caregivers and patients.

Orphanet journal of rare diseases
2025

Characterizing Developmental and Behavioral Profiles in Developmental Synaptopathies to Inform Clinical Trial Endpoints.

American journal on intellectual and developmental disabilities
2025

[The value of simultaneous 18F-FDG PET/MR in detecting intracranial tubers in tuberous sclerosis complex patients with epilepsy and imaging-related factors associated with the presence of tubers in the epileptogenic zone].

Zhonghua yi xue za zhi
2025

SACF and GILA assays on AML12 cells show limited predictive value for mouse liver genotoxicity.

Toxicology and applied pharmacology
2025

Very low-dose Everolimus therapy diminishes cardiac tumours in tuberous sclerosis complex disease.

Cardiology in the young
2025

An interpretable machine learning approach for predicting drug-resistant epilepsy in children with tuberous sclerosis complex.

Frontiers in neurology
Ver todos os 2.677 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Associação brasileira dedicada a Esclerose tuberosa.

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Complexo esclerose tuberosa e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

A condição é causada por alterações genéticas com herança autossômica dominante, principalmente nos genes TSC1 e TSC2. Esses genes produzem as proteínas hamartina e tuberina, que regulam o crescimento e a multiplicação das células no corpo.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 7 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. Tuberous sclerosis complex.
    Nature reviews. Disease primers2026PMID 41820375
  2. ORPHA:805
    Orphanet
  3. GARD:7830
    GARD (NIH)
  4. Q1362721
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Complexo esclerose tuberosa. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/complexo-esclerose-tuberosa

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Complexo esclerose tuberosa
Compêndio · Raras BR

Complexo esclerose tuberosa

ORPHA:805 · MONDO:0001734
🇧🇷 Brasil SUS
SIGTAP
5 procedimentos
Geral
Prevalência
1-9 / 100 000
Herança
Autosomal dominant
CID-10
Q85.1 · Esclerose tuberosa
CID-11
Ensaios
31 ativos
Medicamentos
3 registrados
Início
All ages
Prevalência
1.58 (Taiwan, Province of China)
MedGen
UMLS
C0041341
Repurposing
1 candidato
everolimus — mTOR inhibitor
EuropePMC
Wikidata
Wikipedia
Papers 10a
Evidência
🥇 Ensaio rand.

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Moléculas estudadas na doença
fonte: OpenTargets
Rara